Sponsors (4)
The bill strengthens U.S. medical supply resilience, domestic production, and emergency responsiveness through trusted‑partner trade rules and regulatory alignment, but does so with likely near‑term fiscal and compliance costs, increased trade and political frictions, and risks to privacy, safety standards, and some U.S. suppliers.
Hospitals, health systems, and patients (especially those with chronic conditions) would get more reliable, faster access to medicines, devices, and supplies during crises by diversifying suppliers, expediting cross‑border movement, and allowing targeted trade measures.
U.S. medical manufacturing, R&D, and suppliers could expand through incentives, cooperative R&D and improved access to foreign procurement markets, creating sales opportunities for small manufacturers and researchers.
Regulatory harmonization, standardized definitions, and increased transparency could reduce approval and compliance delays and legal uncertainty, making it easier and quicker for manufacturers to bring medical products to market.
Pursuing diversified supply chains, reshoring incentives, procurement preferences, and related subsidies could raise costs for hospitals and taxpayers and increase federal spending, at least in the near term.
Efforts to change trade rules, designate trusted partners, or restrict sourcing could provoke retaliatory measures or diplomatic/commercial frictions that raise prices and complicate access to low‑cost suppliers.
Reducing trade barriers and fast‑tracking cross‑border flows may expose U.S. manufacturers to stronger foreign competition and market share loss, risking jobs and business viability for some domestic suppliers.
Based on analysis of 7 sections of legislative text.
Authorizes the President to strike "trusted trade partner" agreements to reduce import barriers on medical goods, with required congressional review, monitoring, and enforcement rules.
Official title: Authorize the President to enter into trade agreements for the reciprocal elimination of duties or other import restrictions with respect to medical goods to contribute to the national security and public health of the United States, and for other purposes.
Introduced March 12, 2025 by Thomas Roland Tillis · Last progress March 12, 2025
Allows the President to negotiate and implement "trusted trade partner" agreements with foreign countries to remove or reduce duties, quotas, and import restrictions on medical goods in order to strengthen U.S. medical supply chain resilience, public health, and national security. It creates rules and timelines for administration consultations, mandatory reports to Congress, a congressional review-and-disapproval process before agreements take effect, and ongoing USTR monitoring and enforcement steps if partners fail to meet commitments. The law defines covered terms (medical goods, devices, drugs, trusted trade partner), lists purposes (diversification, regulatory cooperation, IP protection, procurement access, R&D collaboration), sets factors the President must consider before negotiating, requires periodic congressional updates, and prescribes remedies the President may take quickly if a partner breaches commitments.